Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Characteristics of the study subjects

From: Usefulness of measurement of heart rate variability by holter ECG in hemodialysis patients

All patients (n = 90)
Age (year) 63.4 ± 11.8
Gender (f/m) 26:64
Duration of HD (months) 68.4 ± 73.4 (1–328)
Primary Cause of HD, n (%)
 Diabetic Nephropathy 44 (48.9%)
 Chronic glomerulonephritics 30 (33.3%)
 Unknown or others 16 (17.8%)
Body Mass Index (kg/m2) 21.6 ± 3.2
PVC,n (%) 48 (53.3%)
Medication, n (%)
 ARB 54 (60.0%)
 Beta blockers 39 (43.3%)
 48 (53.3%) Ca channel blockers
 ACE 4 (4.4%)
Hemoglobin (g/dl) 10.1 ± 1.1
Albumin (g/dl) 3.9 ± 0.5
pre/postHD Na (mEq/l) 138.3 ± 3.5/139.9 ± 2.1
pre/postHD K (mEq/l) 4.3 ± 0.7/3.3 ± 0.4
pre/postHD Ca (mg/dl) 9.2 ± 1.3/9.5 ± 1.0
Fluid removal (kg) 2.2 ± 1.2
Pre/post HD systolic blood pressure (mmHg) 153.7 ± 19.1/122.3 ± 18.2
Pre/post HD diastolic blood pressure (mmHg) 70.4 ± 14.3/73.1 ± 16.6
  1. PVC premature ventricular contraction, ARB angiotensin receptor blocker, Ca channel blockers calciumchannel blockers, ACE angiotensin-converting enzyme inhibitor